The 3rd Liquid Biopsy Surveillance and Early Detection Summit covers topics such as:
- Spearheading Liquid Biopsy Development for Early Screening to Tailor Personalized Medicines
- Benchmarking Standards to Improve Clinical Utility of CTCs & ctDNA for Patient Monitoring
- Unravelling Liquid Biopsy’s Promise to Monitor CNS Disease to Establish Clinical Validity
- Spearheading Liquid Biopsy Development for Early Screening to Tailor Personalized Medicines
- Benchmarking Standards to Improve Clinical Utility of CTCs & ctDNA for Patient Monitoring
- Unravelling Liquid Biopsy’s Promise to Monitor CNS Disease to Establish Clinical Validity
- Fast-Tracking Reimbursements to Overcome Barriers in Facilitating Patient Access to Early Liquid Biopsies
- Advancing Variability in ctDNA, cfDNA & cfRNA to Assess Molecular Response for Enhanced Technical Analysis
- Implementing Post-Diagnosis Longitudinal Monitoring to Evaluate Tumor Progression & Resistance for Successful Patient ManagementChair:
- Harnessing Microfluidic, Methylation & Fragmentomic Strategies to Characterize Targets for Earlier Detection
The 3rd Liquid Biopsy Surveillance and Early Detection Summit might be held in Boston, United States in Nov 2024.
